SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
JSPR reported Third Quarter 2026 results. The price and volatility reaction is pending.
JSPRearnings

Earnings reactions, page 2

Jasper Therapeutics, Inc. (JSPR) Q3 FY2026 earnings

November 16, 2026 · SharpeIQ Research Desk

Reported results

  • Cash and cash equivalents as of September 30, 2026, totaled $135.3 million.
  • Research and development expense for the three months ended September 30, 2026, was $8.3 million.
  • General and administrative expense for the three months ended September 30, 2026, was $6.4 million.
  • Net loss attributable to common stockholders was $144.5 million for the three months ended September 30, 2026.
  • Revenue for the three months ended September 30, 2026, was $8.0 million.

Guidance

  • Jasper expects to report interim IgAN data from Stage 1 of the renal basket study in the fourth quarter of 2026 and updated data in the first quarter of 2027.
  • First patients in the FSGS expansion cohort are expected to be dosed in the first quarter of 2027.
  • The company expects to present initial data from the briquilimab Phase 1/2 case control study in the fourth quarter of 2026.

Notes

In November 2026, the Company effected a 1-for-30 reverse stock split of its common stock.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-16 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →